Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;33(4):247-52.
doi: 10.5114/ada.2016.61599. Epub 2016 Aug 16.

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases

Agnieszka Wasilewska  1 , Marta Winiarska  1 , Małgorzata Olszewska  1 , Lidia Rudnicka  1
Affiliations
Review

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases

Agnieszka Wasilewska et al. Postepy Dermatol Alergol. 2016 Aug.

Abstract

Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).

Keywords: alopecia areata; fynomer; lichen planus; pemphigoid; pemphigus.

PubMed Disclaimer

References

    1. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–41. - PubMed
    1. Papp K, Berth-Jones J, Kragballe K, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21:1151–60. - PubMed
    1. Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14:559–68. - PubMed
    1. Richards HL, Fortune DG, Main CJ, Griffiths CE. Stigmatization and psoriasis. Br J Dermatol. 2003;149:209–11. - PubMed
    1. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23:613–9. - PMC - PubMed